Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of A4250 (Odevixibat) in Healthy Adults
NCT03608319Phase 1Completed
- Sponsor
- Albireo Pharma
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC) (3 arms), sponsored by Albireo Pharma. Primary endpoints: Maximum observed plasma concentration of A4250 after a high fat meal at 18 hours, Area under the plasma concentration time curve from time zero extrapolated to infinity of A4250 after a high fat meal at 18 hours and 4 more. Started Jul 2018; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT03608319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608319.